Metazosin is an antihypertensive α1-adrenergic receptor antagonist.[1][2]
Names | |
---|---|
IUPAC name
1-[4-(4-Amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-2-methoxypropan-1-one
| |
Other names
Kenosin
| |
Identifiers | |
3D model (JSmol)
|
|
ChemSpider | |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C18H25N5O4 | |
Molar mass | 375.429 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Synthesis
editThe amide (3) is formed when piperazine is reacted with 2-methoxypropionylchloride (2). Metazosin is the product when this intermediate is reacted with the substituted quinazoline (4).[3][4]
References
edit- ^ Trcka, V; König, J; Mácová, S; Smíd, M; Helfert, I; Votavová, M; Remesová, J; Nezádalová, E (1990). "Pharmacology of a new antihypertensive agent, metazosin (Kenosin)". Ceskoslovenska Farmacie. 39 (6): 266–74. PMID 1981860.
- ^ Lapka, R; Rejholec, V; Sechser, T; Peterková, M; Smíd, M (1989). "Interspecies pharmacokinetic scaling of metazosin, a novel alpha-adrenergic antagonist". Biopharmaceutics & Drug Disposition. 10 (6): 581–9. doi:10.1002/bdd.2510100607. PMID 2575403.
- ^ US patent 4775673, Jan Koenig, Miroslav Rajsner, Vaclav Trcka, Sverluse Macova, "Substituted acylpiperazinoquinazolines and pharmaceutical compositions containing same", issued 1988-10-04, assigned to Spofa Spojene Podniky Pro Zdravotnickou Vyrobu
- ^ "Metazosin". chemdrug.com. Retrieved 2024-07-08.